Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Rubicon Research Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹485
Per ShareLot Size
30 Shares
Minimum Investment
₹14,550
Issue Size
₹1,377.5 Cr
Face Value
₹1
Per ShareIPO Type
Book Building
Retail Quota
10%
QIB Quota
75%
NII Quota
15%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
77.34%
Promoter Holding (Post-Issue)
61.79%
Issue Type
Book Building
ISIN
INE506V01022
We are a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets, particularly, the United States. Based on the peer set (of seven listed Indian companies assessed by F&S, and our Company), we are the only Indian pharmaceutical player with a complete focus on regulated markets*. (Source: F&S Report) As on June 30, 2025, we directly or through our Subsidiaries have a portfolio of 72 active ANDA and nine NDA products approved by, and one over-the-counter monograph listed with, the USFDA. As on June 30, 2025, we have 17 new products awaiting USFDA ANDA approval and 63 product candidates in development. Our Company sells branded and non-branded pharmaceutical products, and for the three months ended June 30, 2025, derived 95.05% and 4.95% of our revenue from sale of goods from the sale of non-branded and branded products, respectively. The following table sets forth the therapy area-wise split of our revenue from sale of goods for the three month periods ended June 30, 2025 and 2024, and Fiscals 2025, 2024 and 2023.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offering of up to 28,405,841 equity shares of face value of Re. 1 each ("Equity Shares") of Rubicon Research Limited (Formerly Known as Rubicon Research Private Limited)(the "Company" or the "Issuer") for cash at a price of Rs. 485 per equity share (Including a Share Premium of Rs.484 per equity share) ("Offer Price") aggregating up to Rs. 1377.50 crores (the "Offer") comprising a fresh issue of up to 10,313,058 equity shares of face value of Re. 1 each aggregating up to Rs. 500.00 crores by the company (the "Fresh Issue") and an offer for sale of up to 18,092,783 equity shares of face value of Re. 1 each aggregating up to Rs. 877.50 crores by the promoter selling shareholder, general Atlantic Singapore RR Pvt Ltd (the "Offer for Sale"). This offer includes a reservation of up to 39,863 equity shares of face value of Re.1 each, aggregating up to Rs. 1.75 Crore (Constituting up to 0.02% of the Post-Offer Paid-up Equity Share Capital), for subscription by eligible employees ("Employee Reservation Portion"). The offer less the employee reservation portion is hereinafter referred to as the "Net Offer". the company in consultation with the BRLMS, may offer a discount of up to Rs.46 to the offer price (Equivalent of Rs.46 Per Equity Share) to eligible employees bidding in the employee reservation portion ("Employee Discount"). the offer and the net offer shall constitute at least 17.24% and 17.22%, respectively, of the post-offer paid-up equity share capital of the company. A discount of Rs. 46 per equity share is being offered to eligible employees bidding in the employee reservation portion.
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
In 2024, the US dominated the global prescription pharmaceutical market with a commanding 46.9% share. This dominance is attributed to several factors, including a robust healthcare infrastructure, a favorable regulatory environment, an innovative reimbursement mechanism, significant investments in R&D, and a large population with high healthcare expenditure and affordability. Additionally, according to F&S, the US leads in the share of first launches globally, with 65% of new medicines launched in 2021 being first launched in the US.
Our Company was incorporated on May 6, 1999, as a private limited company under the Companies Act, 1956, under the name `Rubicon Consultants Private Limited', pursuant to a certificate of incorporation issued by the Registrar of Companies, Maharashtra at Mumbai ("RoC"). Subsequently, pursuant to a resolution passed by our Board and by our Shareholders on May 6, 2002 and June 15, 2002, respectively, the name of our Company was changed from `Rubicon Consultants Private Limited' to `Rubicon Research Private Limited' as we had set-up a pharma research laboratory, entered into contracts with customers from the pharma industry and was in the process of making applications to secretary, Department of Scientific and Industrial Research, Ministry of Science and Technology for carrying on scientific research development in our laboratories, consequent to which a fresh certificate of incorporation was issued by the RoC dated September 2, 2002 under the Companies Act, 1956. Furthermore, our Company's status was converted from a private limited company to a public limited company pursuant to a resolution passed by our Board and by our Shareholders on April 11, 2024 and May 13, 2024, respectively, the name of our Company was changed from `Rubicon Research Private Limited' to `Rubicon Research Limited' under Companies Act, 2013. A fresh certificate of incorporation dated July 23, 2024 was issued by the registrar of companies, central processing centre, Manesar, Haryana consequent to our Company's conversion into a public limited company.
Wholesaler and Retailer
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.